BridgeBio Oncology Therapeutics, Inc (BBOT) Sharpe Ratio

Sharpe ratio is not yet available for BBOT. This metric requires at least 12 months of historical daily returns to calculate. Check back once this data is available.

How it compares to other similar stocks

The table compares BridgeBio Oncology Therapeutics, Inc's Sharpe Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how BBOT's risk-adjusted performance compares to industry peers.

Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jun 5, 2026.

Symbol	Name	1Y Sharpe Ratio
RVMDW	Revolution Medicines Inc. Warrant	14.24
SLGL	Sol-Gel Technologies Ltd.	9.11
CLYM	Climb Bio Inc	7.55
ERAS	Erasca, Inc.	7.50
TNGX	Tango Therapeutics, Inc.	6.69
NBTX	Nanobiotix S.A.	6.56
DRTSW	Alpha Tau Medical Ltd. Warrant	6.34
OVID	Ovid Therapeutics Inc.	6.24
RLMD	Relmada Therapeutics, Inc.	6.20
ORKA	Oruka Therapeutics, Inc	5.80
BBOT	BridgeBio Oncology Therapeutics, Inc	—

Benchmark Against

Benchmark

S&P 500 Index

Lookback Period

How to choose period

Historical Sharpe Ratio

The chart shows BBOT's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when BBOT consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.

Loading charts...

Sharpe Ratio Calculator

How does BBOT fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio